Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Stoke Therapeutics, Inc.’s reported figures.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
FAQ
- What is Stoke Therapeutics, Inc.'s EBIT?
- Stoke Therapeutics, Inc. (STOK) reported EBIT of -$53.42M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s EBIT changed year-over-year?
- Stoke Therapeutics, Inc.'s EBIT decreased by 148.0% year-over-year, from $111.24M to -$53.42M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s EBIT has grown at a -30.1% compound annual growth rate (CAGR), from -$86.07M to -$20.59M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Stoke Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude